P. Odin, R. Pahwa, Jill M. Farmer, T. Kimber, B. Bergmans, E. F. Álvarez, K. Chaudhuri, Resmi Gupta, C. Yan, L. Bergmann, P. Kukreja, A. Antonini
{"title":"通过口服治疗控制不充分的帕金森病患者的特征:Foslevodopa/Foscarbidopa 3期临床项目的基线特征(P2-11.006)","authors":"P. Odin, R. Pahwa, Jill M. Farmer, T. Kimber, B. Bergmans, E. F. Álvarez, K. Chaudhuri, Resmi Gupta, C. Yan, L. Bergmann, P. Kukreja, A. Antonini","doi":"10.1212/wnl.0000000000202205","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":334567,"journal":{"name":"Sunday, April 23","volume":"31 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Characterizing a Parkinson’s Disease Population Inadequately Controlled by Oral Therapy: Baseline Characteristics of the Phase 3 Clinical Program for Foslevodopa/Foscarbidopa (P2-11.006)\",\"authors\":\"P. Odin, R. Pahwa, Jill M. Farmer, T. Kimber, B. Bergmans, E. F. Álvarez, K. Chaudhuri, Resmi Gupta, C. Yan, L. Bergmann, P. Kukreja, A. Antonini\",\"doi\":\"10.1212/wnl.0000000000202205\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":334567,\"journal\":{\"name\":\"Sunday, April 23\",\"volume\":\"31 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-04-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Sunday, April 23\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1212/wnl.0000000000202205\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sunday, April 23","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1212/wnl.0000000000202205","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Characterizing a Parkinson’s Disease Population Inadequately Controlled by Oral Therapy: Baseline Characteristics of the Phase 3 Clinical Program for Foslevodopa/Foscarbidopa (P2-11.006)